7467-12-1

Basic information

• Product Name: Benzenesulfonamide, 2,4-dimethyl- (9CI)
• Synonyms: Benzenesulfonamide, 2,4-dimethyl- (9CI);Benzenesulfonamide,2,4-dimethyl-
• CAS NO: 7467-12-1
• Molecular Formula: C₈H₁₁NO₂S
• Molecular Weight: 185.24344
• EINECS: 231-261-0
• Product Categories: SULFONAMIDE
• Mol File: 7467-12-1.mol
• Article Data: 10

Chemical Properties

• Melting Point: 139～141℃
• Boiling Point: 336.9 °C at 760 mmHg
• Flash Point: 157.5 °C
• Appearance: /
• Density: 1.227 g/cm³
• Vapor Pressure: 0.000109mmHg at 25°C
• Refractive Index: 1.554
• PKA: 10.30±0.60(Predicted)
• CAS DataBase Reference: Benzenesulfonamide, 2,4-dimethyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonamide, 2,4-dimethyl- (9CI)(7467-12-1)
• EPA Substance Registry System: Benzenesulfonamide, 2,4-dimethyl- (9CI)(7467-12-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 7467-12-1(Hazardous Substances Data)

Usage

General Description

Benzenesulfonamide, 2,4-dimethyl- (9CI) is a chemical compound with the molecular formula C8H11NO2S. It is a derivative of sulfonamide, which is a class of compounds known for their antibacterial and diuretic properties. This particular compound, 2,4-dimethyl-benzenesulfonamide, is used in the synthesis of pharmaceuticals and agrochemicals. It is also a key building block in the production of various dyes, pigments, and polymers. Additionally, it has been studied for its potential use in the treatment of various medical conditions, including cancer and infectious diseases. Overall, benzenesulfonamide, 2,4-dimethyl- (9CI) is a versatile and important chemical with a wide range of industrial and medical applications.

InChI:InChI=1/C8H11NO2S/c1-6-3-4-8(7(2)5-6)12(9,10)11/h3-5H,1-2H3,(H2,9,10,11)

Upstream product

• 609-60-9 2,4-dimethylbenzenesulfonyl chloride 
• 2905-29-5 2,6-dimethyl-benzene-sulfonyl chloride 
• 257953-14-3 N-ethyl-2,4-dimethylbenzenesulfonamide 
• 13616-82-5 2,4-dimethyl-thiophenol 

Downstream Products

• 6325-82-2 N-xanthen-9-yl-m-xylene-4-sulfonamide 
• 670255-96-6 N-(2,4-dimethyl-benzenesulfonyl)-glycine 
• 885440-93-7 1-[(2,4-dimethylphenyl)sulfonyl]-1H-pyrrole 
• 1009604-24-3 (palladium)2Cl₂(2,4-dimethylphenylsulfonamide)2 

Relevant articles and documents

Mechanism of Action of an EPAC1-Selective Competitive Partial Agonist

The exchange protein activated by cAMP (EPAC) is a promising drug target for a wide disease range, from neurodegeneration and infections to cancer and cardiovascular conditions. A novel partial agonist of the EPAC isoform 1 (EPAC1), I942, was recently discovered, but its mechanism of action remains poorly understood. Here, we utilize NMR spectroscopy to map the I942-EPAC1 interactions at atomic resolution and propose a mechanism for I942 partial agonism. We found that I942 interacts with the phosphate binding cassette (PBC) and base binding region (BBR) of EPAC1, similar to cyclic adenosine monophosphate (cAMP). These results not only reveal the molecular basis for the I942 vs cAMP mimicry and competition, but also suggest that the partial agonism of I942 arises from its ability to stabilize an inhibition-incompetent activation intermediate distinct from both active and inactive EPAC1 states. The mechanism of action of I942 may facilitate drug design for EPAC-related diseases.

Preparation method and medical application of benzisothiazole and benzothiophene

The invention discloses a preparation method and medical application of benzisothiazole and benzothiophene, and telates to the field of pharmaceutical chemistry. According to the invention, benzisothiazole and benzothiophene are the first type of HIF-2 agonists; compared with a compound M1001 found by the applicant in the earlier stage, the invention has better HIF-2 agonist activity, and has remarkable enhancement activity on expression of mRNA and protein of EPO, VGEF, Glut1, NDRG1 and the like at the downstream of HIF-2, so that the invention can be used for preparing drugs for treating and/or preventing chronic kidney diseases/chronic renal anemia, dyslipidemia and high cholesterol caused by abnormal expression of HIF-2; and the method has a good industrialization prospect.

Palladium-Catalyzed ortho-Benzoylation of Sulfonamides through C?H Activation: Expedient Synthesis of Cyclic N-Sulfonyl Ketimines

The ortho-carbonylation of sulfonylarenes by non-hazardous aryl aldehydes as a carbonyl precursor was reported. In this method, the sulfonamide group serves as a directing group for C?H activation in the presence of a Pd catalyst under ligand-free conditions. The scope of this strategy has been extended to the one-pot two-step synthesis of cyclic N-sulfonyl ketimines under mild reaction conditions. Our approach could be considered as an alternative by circumventing the use of highly reactive organolithium or Grignard reagents to access a wide range of biologically potent cyclic N-sulfonyl ketimines. (Figure presented.).